Cannabis Law Report

OCTOBER 12, 2021

Leveraging its deep expertise in nucleic acid-based technologies, the Company has also established safeCircle™, a pooled COVID-19 testing program that is grounded in the Company’s EUA-authorized Linea™ COVID-19 Assay Kit. Testing began this week and is available to asymptomatic students, faculty, and staff on a voluntary basis.

Programs 52

Programs Clinical Trials Research and Development Therapy 52

Cannabis Law Report

JUNE 30, 2021

s (CSE: MXT) (OTC: MXTTF) SHAMAN and YMI programs apply machine learning to high-resolution health records to better diagnose mental health disorders. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Cannabis Law Report

DECEMBER 26, 2021

December 17, 2021 ·. – December 16, 2021) – Entheon Biomedical Corp. In furtherance of its program, the Company filed US Provisional Patent Application No. 63/283,051, titled “Detection of Therapeutic Psychedelic State,” as of November 23, 2021. Vancouver, British Columbia–(Newsfile Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

JUNE 7, 2021

NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. 1.526 were reduced as expected and consistent with other CDC-reported data on vaccine-induced antibody neutralization against these variants 1. P1 (Brazil), and B.1.526

Clinical Trials 64

Clinical Trials Research and Development Therapy Supply Chain 64

Cannabis Law Report

NOVEMBER 12, 2021

(Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the first quarter of its fiscal year ending June 30, 2022 and reported recent business highlights. million as of September 30, 2021.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

SpeedWeed

SEPTEMBER 17, 2021

Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI. Wesana outlined five key goals: Gain expertise and information to design psychedelic-assisted therapy programs for TBI and improve the Wesana timeline and path to market for its treatments.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

SpeedWeed

AUGUST 11, 2021

The grant comes from Michigan’s 2021 Veteran Marijuana Research Grant Program , and is funded by the state’s recreational cannabis taxes. We overcame significant regulatory obstacles obstructing cannabis research to conduct the first clinical trial of inhaled cannabis for PTSD ,” said Yazar-Klosinki. .

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Cannabis Law Report

NOVEMBER 15, 2021

Virpax” or the “Company”) (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments. “We On July 30, 2021, Virpax announced the appointment of Gerald W. On August 17, 2021, Virpax announced that it had received FDA response and guidance on AnQlar.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

SEPTEMBER 2, 2021

– Company’s safeCircle™ Testing Program to Monitor for COVID-19 Among On-Campus Unvaccinated Populations –. Testing is scheduled to begin in the second half of September 2021. Under the Contract, ADCL will deploy safeCircle™, its high-throughput, pooled COVID-19 testing program, to provide cost-effective COVID-19 testing.

Clinical Trials 99

Clinical Trials Research and Development Therapy Collective 99

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

DECEMBER 21, 2021

Numinus also made important alliances in 2021, particularly with the Multidisciplinary Association for Psychedelic Studies (MAPS) on its compassionate access trial for MDMA-assisted therapy. While its psilocybin and MDMA trials progress, the company is expanding its psychedelics research laboratory.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

MAY 29, 2022

In May 2021, a Nature Medicine study showed the benefits of MDMA in relieving post-traumatic stress disorder. [4] 4] In April 2021, a separate study from the New England Journal of Medicine demonstrated the efficacy of psilocybin in reducing symptoms of depression. [5] Clinical Trials and Human Subject Protections.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. The MDMA Therapy Training Program was created to train the next generation of psychedelic therapists. Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JULY 28, 2021

Advance to FDA IND-enabling studies to support human clinical studies. – July 28, 2021) – PharmaDrug Inc. The results also provide confidence in the Company’s plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

AUGUST 3, 2021

– Full Service, Turnkey Solution Anchored by Applied DNA Clinical Labs’ safeCircle™ Pooled COVID-19 Testing to Be Deployed Across All 25 CUNY Campuses to Facilitate Fall Re-Opening –. Fiscal 2021 Third Quarter Financial Results and Investor Conference Call. million, and contains no minimum weekly testing commitment.

Clinical Trials 105

Clinical Trials Therapy Collective Research and Development 105

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52

Veriheal

AUGUST 31, 2020

Program between St. About Sinibaldo: Sinibaldo is an aspiring healthcare professional and a biomedical researcher in the Medical Scientist Training Program (M.D./Ph.D.) About Nishtha: Nishtha is pursuing neurology to become a physician-scientist in honor of her grandmother Nani who suffered from Alzheimer’s.

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

NOVEMBER 15, 2021

CRO orders typically provide a means to evaluate LinearDNA within a customer’s preclinical development program. 2021 Aug 26;23:119-127. eCollection 2021 Dec 10. Hurry, 917-733-5573, sanjay.hurry@adnas.com Program Manager: Brian Viscount, 631-240-8877, brian.viscount@adnas.com Web: www.adnas.com Twitter: @APDN.

Research and Development 52

Research and Development Therapy Clinical Trials Supply Chain 52

Cannabis Law Report

JUNE 2, 2021

Aggregate testing results will be reported to the director of the summer camp via safeCircle’s integration with CLEARED4, the Company’s pooled surveillance testing program partner, through CLEARED4’s smartphone-based online health safety management and reporting solution. Testing will be conducted from mid-June through end-July.

Clinical Trials 82

Clinical Trials Therapy Research and Development Collective 82

Cannabis Law Report

NOVEMBER 29, 2021

Published on November 30, 2021. The potential real-life impact – keeping in mind that these data were generated under stringent clinical trial conditions and without any tailoring to the specific needs of the individual – could be even more transformative for those patients suffering from TRD. 18 articles.

Treatment 52

Treatment Clinical Trials Data Patients 52

TheAnswerPage

JANUARY 11, 2022

As a result, state medical marijuana rules and regulations have focused on the demands of the public without putting significant emphasis on the scientific data or the ability of the medical community to support and care for medical marijuana patients. Nov 24 2021. Journal of Clinical Gynecology and Obstetrics, North Amer, 0 Nov 2021.

Patients 98

Patients Education Marijuana Therapy 98

Cannabis Law Report

DECEMBER 7, 2021

Scientific Reports volume 11 , Article number: 23462 ( 2021 ) Cite this article. However, despite the increased use of MCs in children, there is limited data regarding their safety and efficacy in this population for those different indications 11. Data extraction. Stolar & Ilan Matok. Metrics details.

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

DECEMBER 21, 2021

SAN DIEGO–(BUSINESS WIRE)– $DFCO #CleanEnergy — Dalrada Corporation (OTCQB: DFCO , “Dalrada”) would like to express its sincere appreciation for its investors, shareholders, staff and followers for their support throughout 2021. from 2021 to 2028. from 2021 to 2030. billion (2020).

Research and Development 52

Research and Development Supply Chain Data Business 52

Cannabis Law Report

JUNE 1, 2021

Company remains on track for potential approval of Vicineum™ in the US in August 2021. Drake received her bachelor’s degree from Wichita State University and is a graduate of the Harvard Business School Executive Leadership Program. CAMBRIDGE, Mass.–(BUSINESS The Company intends to grant non-statutory stock options to Ms.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Alchimia

JANUARY 25, 2022

Assuming clinical trials go well, the ultimate hope of the researchers is to develop a pill containing purified versions of these acidic cannabinoids as an adjunct to vaccination, for use after known exposure or by those who are immunocompromised. The Oregon State University study that has gone viral (pun intended).

Research and Development 98

Research and Development Terpenes CBD Treatment 98

Puff Puff Post

DECEMBER 28, 2018

An official study is aimed to conclude in July of 2019, where we’ll see all the data which comes forth. No single program or treatment is best, and specially tailored treatments based off the child’s needs are found to be most effective. It’s aimed to discover any aberrant behavior differences with the use of CBD versus placebo.

Treatment 76

Treatment Oil CBD Therapy 76

Cannabis Law Report

JUNE 4, 2021

This list is focused on those who have had the largest impact for 2021. . Tim Ferriss is Psychedelics Invest’s number one most influential person for 2021 because of his support through his funding, utilization of his multiple massive social outlets, and his continued balanced message about the efficacy and realities of psychedelic medicines.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

Cannabis Law Report

JANUARY 20, 2022

ELE-Psilo program expected to enter clinical trials in Q2 2022 and to target the pressing need for rapid-acting antidepressants compatible with existing healthcare infrastructure and insurance. Eleusis secured an Innovation Passport Designation for ELE-Psilo in adult treatment-resistant depression under the U.K.

Therapy 52

Therapy Research and Development Business Access 52